A Higher Score on the Dermatology Life Quality Index, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis

Ekelund, Mats; Mallbris, Lotus; Qvitzau, Susanne; Stenberg, Berndt

doi:10.2340/00015555-1591

Cited by 16 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[25][26][27] Finally, the analyses apply to comparisons of secukinumab versus ustekinumab and etanercept because head-to-head trial data were available for these treatments; similar analyses with different psoriasis comparators could yield different findings. First, this is a post hoc analysis.…”

Section: Discussionmentioning

confidence: 99%

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Warren

Halliday

Graham

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Warren

Halliday

Graham

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…A recent study by Ekelund et al [16] estimated that high DLQI scores are associated with high medication costs. In this study, PASI scores were not significantly associated with medication costs.…”

Section: Discussionmentioning

confidence: 99%

The Costs of Psoriasis Medications

Mustonen

Mattila

Leino

et al. 2013

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionPsoriasis is a chronic disease, which contributes to the economic burden on health care. The distribution of psoriasis medication costs and the quality of life in these patients has been estimated to be around 20% of total costs.ObjectivesTo estimate the economic distribution of medications and the impact of multiple treatment options on a patient’s quality of life.Materials and methodsThe study was based on 236 Finnish psoriasis patients. The Finnish Social Insurance Institution had databases for all psoriasis related medications purchased. Each purchase, during the 1-year study period (1 October 2009–30 September 2010), was recorded and analyzed. The dermatological quality-of-life index was collected from the medical records.ResultsTotal medication costs were €1,083 per year per patient. Topical treatments were the most often purchased medication and they comprised 18% of the total medication costs. Ten percent of the patients needed 3 or more medication changes during the 1-year study period. Biologics were used only by 5% of patients, but they produced 67% of total medication costs. Patients needing various treatments had higher medication costs and a poorer quality of life.ConclusionA small number of patients generated a great sum of medication costs partly due to the need to change medications. These patients had the worst quality-of-life index scores. Biologics formed a major cost component.Electronic supplementary materialThe online version of this article (doi:10.1007/s13555-013-0040-z) contains supplementary material, which is available to authorized users.

show abstract

“…Az AP mellett bármilyen súlyosságú bőrtünetekkel rendelkező betegeket is beválasztva további két olyan közle-ményt találtunk, amelyek direkt vagy összes költségada-tot közölnek az AP-val asszociált betegcsoportra [35,36].…”

Section: áBraunclassified

Disease burden of psoriasis associated with psoriatic arthritis in Hungary

et al. 2014

View full text Add to dashboard Cite

Bevezetés: A psoriasis a leggyakoribb krónikus, szisztémás, immunmediált gyulladásos kórkép, amely elsősorban a bőrt és az ízületeket érintheti. Célkitűzés: Arthritis psoriaticával társuló középsúlyos és súlyos psoriasisos betegek életmi-nőségének és betegségköltségeinek vizsgálata. Módszer: Két egyetemi bőrgyógyászati klinikán keresztmetszeti kérdő-íves felmérést végeztek. Eredmények: A vizsgált 57 beteg (65% férfi ) átlagéletkora 54,3±11,6 év, életminősége az EQ-5D indexszel mérve 0,48±0,4 volt. Az egy betegre jutó éves átlagköltség 2,56 millió Ft, amelyből 71% a bioló-giai terápiához kapcsolódó költség és 21% az indirekt költség. Az indirekt költség 95%-a, 506 ezer Ft/beteg/év a psoriasis miatti munkából való kiesés miatt jelentkezik. A szisztémás kezelésben nem részesülő (21%), a tradicionális szisztémás (32%) és a biológiai szisztémás terápiában részesülő (47%) betegek egy betegre jutó éves átlagköltsége sorrendben 493 ezer Ft, 513 ezer Ft és 4,84 millió Ft. Következtetések: A biológiai terápia szignifi káns életminőség-javulást eredményez. Mivel az arthritis psoriaticával társuló psoriasis-betegcsoportban a szisztémás kezelések mindkét kórképben hatásosak, ezért a terápiával elérhető egészségnyereség mérése egészség-gazdaságtani szempontból a két kórkép esetén együttesen is célszerű, mert a valós egészséghaszon nagyobb lehet, mintha csak az egyik kórképet vizsgáljuk. Orv. Hetil., 2014, 155(48), 1913-1921 Kulcsszavak: psoriasis, arthritis psoriatica, biológiai terápia, életminőség, költség, Magyarország Disease burden of psoriasis associated with psoriatic arthritis in HungaryIntroduction: Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. Aim: To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. Method: A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. Results: Fifty-seven patients (65% males) completed the survey with a mean age of 54.3±11.6 years and mean EQ-5D score of 0.48±0.4. Mean annual total cost was €8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for €1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of €1,729, €1,799, and €16,983, respectively. Conclusions: Patients on biological therapy showed signifi cantly better health related quality of life. As for health economics, the effi cacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately.

show abstract

A Higher Score on the Dermatology Life Quality Index, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis

Cited by 16 publications

References 15 publications

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

The Costs of Psoriasis Medications

Disease burden of psoriasis associated with psoriatic arthritis in Hungary

Contact Info

Product

Resources

About